Erik Sjögren

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 14

Top Venues

Molecular pharmaceutics

CPT: pharmacometrics & systems pharmacology

Pharmaceutics

Pharmetheus

Uppsala Universitet Farmaceutiska fakulteten (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Pharmetheus

Sweden

Senior Consultant

Uppsala Universitet Farmaceutiska fakulteten

Sweden

Researcher / Assoc. Prof. :: Farmaci

Education History

Uppsala Universitet Farmaceutiska fakulteten

Sweden

PHD :: Farmaci

Uppsala Universitet Farmaceutiska fakulteten

Sweden

MSC

Publications

Luna Prieto Garcia, Anna Vildhede, Pär Nordell, Christine Ahlström, Ahmed B Montaser, Tetsuya Terasaki, Hans Lennernäs, Erik Sjögren
Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Luna Prieto Garcia, Anna Vildhede, Pär Nordell, Christine Ahlström, Ahmed B Montaser, Tetsuya Terasaki, Hans Lennernäs, Erik Sjögren
Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Luna Prieto Garcia, Anna Vildhede, Pär Nordell, Christine Ahlström, Ahmed B Montaser, Tetsuya Terasaki, Hans Lennernäs, Erik Sjögren
Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Luna Prieto Garcia, Anna Vildhede, Pär Nordell, Christine Ahlström, Ahmed B Montaser, Tetsuya Terasaki, Hans Lennernäs, Erik Sjögren
Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins. CPT: pharmacometrics & systems pharmacology (2024)
Michael E Cloesmeijer, Erik Sjögren, Sjoerd F Koopman, Peter J Lenting, Marjon H Cnossen, Ron A A Mathot, null null
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space. CPT: pharmacometrics & systems pharmacology (2024)
Luna Prieto Garcia, Anna Lundahl, Christine Ahlström, Anna Vildhede, Hans Lennernäs, Erik Sjögren
Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction. CPT: pharmacometrics & systems pharmacology 11 (9) (2022)
Erik Sjögren, Joel Tarning, Karen I Barnes, E Niclas Jonsson
A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children. Pharmaceutics 13 (2) (2021)
Johanna Eriksson, Helena Thörn, Erik Sjögren, Lisa Holmstén, Katarina Rubin, Hans Lennernäs
Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model. Molecular pharmaceutics 16 (7) (2019)
Ilse R Dubbelboer, Elsa Lilienberg, Erik Sjögren, Hans Lennernäs
A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition. Molecular pharmaceutics 14 (3) (2017)
Ilse R Dubbelboer, Elsa Lilienberg, Amar Karalli, Rimma Axelsson, Torkel B Brismar, Charlotte Ebeling Barbier, Agneta Norén, Frans Duraj, Mikael Hedeland, Ulf Bondesson, Erik Sjögren, Per Stål, Rickard Nyman, Hans Lennernäs
Reply to "Comment on 'In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma'". Molecular pharmaceutics 15 (1) (2017)
Carl Roos, David Dahlgren, Erik Sjögren, Christer Tannergren, Bertil Abrahamsson, Hans Lennernäs
Regional Intestinal Permeability in Rats: A Comparison of Methods. Molecular pharmaceutics 14 (12) (2017)
David Dahlgren, Carl Roos, Anders Lundqvist, Christer Tannergren, Peter Langguth, Markus Sjöblom, Erik Sjögren, Hans Lennernäs
Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker 51Cr-EDTA. Molecular pharmaceutics 14 (12) (2017)
Elsa Lilienberg, Ilse R Dubbelboer, Amar Karalli, Rimma Axelsson, Torkel B Brismar, Charlotte Ebeling Barbier, Agneta Norén, Frans Duraj, Mikael Hedeland, Ulf Bondesson, Erik Sjögren, Per Stål, Rickard Nyman, Hans Lennernäs
In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. Molecular pharmaceutics 14 (2) (2017)
Carl Roos, David Dahlgren, Staffan Berg, Jan Westergren, Bertil Abrahamsson, Christer Tannergren, Erik Sjögren, Hans Lennernäs
In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations. Molecular pharmaceutics 14 (12) (2017)

Erik Sjögren.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Erik Sjögren